Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

casirivimab/imdevimab

casirivimab/imdevimab
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
REGN-COV2 (Regeneron) INJECTION, INTRAVENOUS 120 mg/mL      
Comments:

Due to high frequency of the Omicron variant, casirivimab and imdevimab are NOT currently authorized in any U.S. region. 

 

 

[FormWeb page pending further updates]

Administration Considerations:

Pediatric ED

  • Use casirivimab/imdevimab (REGN-COV2)- may be administered subcutaneously (or IV).

Main ED/ ED OBS / OB ED

  • Bamlanivimab-etesevimab preferred for IV orders 
  • May use casirivimab/imdevimab (REGN-COV2) IV if needed
  • May use casirivimab/imdevimab (REGN-COV2) subcutaneously if:
    • No IV access AND
    • Prescriber feels patient will not go to Fever & Flu Clinic for infusion

Inpatient (MAIN & HHWC)

  • Must be administered as intravenous infusion
  • Must meet all EUA criteria
    • Must NOT be admitted for treatment of COVID-19 nor have progressing COVID-19 symptoms
    • Presence of COVID19 is an incidental finding.

 

 

Reviewed: December 2020 (Casirivimab/imdevimab)

Last updated: Mar. 2, 2022






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved